Reconstitution and optimisation of the biosynthesis of bacterial sugar pseudaminic acid (Pse5Ac7Ac) enables preparative enzymatic synthesis of CMP-Pse5Ac7Ac by Chidwick, Harriet et al.
This is a repository copy of Reconstitution and optimisation of the biosynthesis of bacterial
sugar pseudaminic acid (Pse5Ac7Ac) enables preparative enzymatic synthesis of CMP-
Pse5Ac7Ac.




Chidwick, Harriet, Flack, Emily, Keenan, Tessa et al. (3 more authors) (Accepted: 2021) 
Reconstitution and optimisation of the biosynthesis of bacterial sugar pseudaminic acid 
(Pse5Ac7Ac) enables preparative enzymatic synthesis of CMP-Pse5Ac7Ac. Scientific 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4756  | https://doi.org/10.1038/s41598-021-83707-x
www.nature.com/scientificreports
Reconstitution and optimisation 
of the biosynthesis of bacterial 
sugar pseudaminic acid 
(Pse5Ac7Ac) enables 
preparative enzymatic synthesis 
of CMP‑Pse5Ac7Ac
Harriet S. Chidwick1, Emily K. P. Flack1, Tessa Keenan1, Julia Walton1, Gavin H. Thomas2 & 
Martin A. Fascione1*
Pseudaminic acids present on the surface of pathogenic bacteria, including gut pathogens 
Campylobacter jejuni and Helicobacter pylori, are postulated to play influential roles in the etiology 
of associated infectious diseases through modulating flagella assembly and recognition of bacteria 
by the human immune system. Yet they are underexplored compared to other areas of glycoscience, 
in particular enzymes responsible for the glycosyltransfer of these sugars in bacteria are still to be 
unambiguously characterised. This can be largely attributed to a lack of access to nucleotide‑activated 
pseudaminic acid glycosyl donors, such as CMP‑Pse5Ac7Ac. Herein we reconstitute the biosynthesis 
of Pse5Ac7Ac in vitro using enzymes from C. jejuni (PseBCHGI) in the process optimising coupled 
turnover with PseBC using deuterium wash in experiments, and establishing a method for co‑factor 
regeneration in PseH tunover. Furthermore we establish conditions for purification of a soluble CMP‑
Pse5Ac7Ac synthetase enzyme PseF from Aeromonas caviae and utilise it in combination with the C. 
jejuni enzymes to achieve practical preparative synthesis of CMP‑Pse5Ac7Ac in vitro, facilitating future 
biological studies.
Pseudaminic acids are non-mammalian nonulosonic acid sugars present in glycoconjugates on the surface of a 
number of pathogenic  bacteria1,2, including multidrug resistant Pseudomonas aeruginosa3–6 and Acinetobacter 
baumannii7–9, and gut pathogens Campylobacter jejuni10–12 and Helicobacter pylori13. The parent sugar α-5,7-diace-
tamido-3,5,7,9-tetradeoxy-l-glycero-l-manno-non-2-ulosonic acid, or Pse5Ac7Ac 1 (often referred to as simply 
pseudaminic acid, or 5,7-diacetyl pseudaminic acid)1,2, shares structural similarities with the widely known 
sialic acid Neu5Ac 214,15, but is relatively understudied in comparison (Fig. 1). For example, glycosyltransferase 
enzymes that catalyse the attachment of pseudaminic acid sugars to proteins or glycans are yet to be unequivo-
cally characterised despite mounting evidence that pseudaminic acid glycosylation of flagella is important for 
autoagglutination and bacterial mobility in both C. jejuni16 and H. pylori13 and may also modulate the host’s 
immune response to bacterial  infection17. A major reason for this relative lack of progress is that chemical access 
to pseudaminic acid derivatives such as nucleotide-activated cytidine monophosphate (CMP)-Pse5Ac7Ac 3, 
required for the study of Leloir glycosyltransferases, is challenging due to their complex structural  architecture18. 
Exploiting Pse5Ac7Ac biosynthetic pathways from bacteria offers an enticing alternative to overcome this 
challenge, particularly as the biosynthesis of CMP-Pse5Ac7Ac 3 is well established in C. jejuni and H. pylori. 
Indeed the H. pylori biosynthetic enzymes PseB (a dehydratase/epimerase), PseC (an aminotransferase), PseH (an 
acetyl transferase), PseG (a nucleotidase), PseI (a Pse5Ac7Ac synthase) and PseF (a CMP-Pse5Ac7Ac synthetase) 
have previously been coopted for the in vitro synthesis of the glycosyl donor 3 from UDP-GlcNAc 4 starting 
material (Scheme 1)19. However this purely enzymatic workflow has yet to be adopted by the glycoscience com-
munity at large as a practical route to CMP-Pse5Ac7Ac 3. Herein we examine the in vitro reconstitution of the 
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C. jejuni Pse5Ac7Ac biosynthetic pathway, and use negative ion LCMS analysis to optimise the workflow. In the 
process we minimise byproduct formation in the coupled transformation catalysed by PseB/C20, and establish a 
method for regeneration of the expensive co-factor acetyl-coenzyme A 5 (Ac-CoA) in the PseH catalysed step, 
which increases the practical and economic viability of the enzymatic process. In addition we purify a soluble 
active PseF enzyme from Aeromonas caviae enabling the preparative synthesis of CMP-Pse5Ac7Ac 3 on a multi-
milligram scale.
Results
Pseudaminic acid biosynthetic enzyme production. Cognisant that scaleable in vitro enzymatic syn-
thesis of CMP-Pse5Ac7Ac 3 would be dependant on ready access to the six biosynthetic enzymes, PseBCHGIF 
(Scheme 1)20, we initially set out to attain the large scale production of the recombinant enzymes. Expression 
trials in E. coli BL21 (DE3) cells, using plasmids encoding N-terminal His-tagged PseC, PseH, PseG, PseI, and 
C-terminal His-tagged PseB genes from C. jejuni, imaged on SDS-PAGE displayed overexpressed enzymes at 
the predicted molecular weight for the desired enzyme and allowed for identification of induction conditions 
(Table 1, Supplementary Fig. SI.1). The production of the PseB, PseH, PseG and PseI enzymes routinely afforded 
mg/L yields of protein post-purification, greater or equal to those previously reported (Table 1, Fig. 2)20. How-
ever, the PseC enzyme displayed a propensity to precipitate during purification when expressed at an induction 
temperature of 37 °C over 4 h. We therefore explored reducing the temperature to 16 °C, which reduced the 
concentration of protein produced but also precipitation post purification. These conditions were therefore used 
in future large scale protein preparations. Unfortunately the N-terminal His-tagged H. pylori PseF enzyme was 
largely insoluble in all expression conditions trialled in our hands (Supplementary Fig. SI.2), we therefore turned 
our attention to the PseF homologue from A. caviae, a gram negative bacterium which presents Pse5Ac7Ac 1 
on its  flagella21. Expression of A. caviae PseF was investigated in E. coli BL21 (DE3) cells with induction condi-
tions of 0.1 mM IPTG followed by three hours incubation at 30 °C found to yield soluble protein at ~13 mg L−1 
post purification. The enzyme was characterised by mass spectrometry, circular dichroism and size exclusion 
chromatography-multi-angle laser light scattering (SEC-MALS) (Supplementary Fig. SI.4–6), which confirmed 
it existed as a homodimer, consistent with homologous CMP-Neu5Ac  synthetase22 and CMP-Kdo  synthetase23. 
Furthermore the activity of the enzyme as a CMP-Pse5Ac7Ac synthetase was confirmed in small scale negative 
ion ESI-LCMS assays with Pse5Ac7Ac 1 and CTP (Supplementary Fig. SI.7). Notably all enzymes could be stored 
in the freezer without cryoprotectant prior to use. 
Figure 1.  The nonulosonic acids; Pse5Ac7Ac 1 and Neu5Ac 2.
Scheme 1.  H. pylori/C. jejuni biosynthetic pathway from UDP-GlcNAc 4 to CMP-Pse5Ac7Ac 319.
Table 1.  Conditions used in the induction of Pse5Ac7Ac biosynthetic enzymes and the resulting quantity of 
enzyme.
Molecular weight/kDa IPTG  concn/mM Induction temp/°C Induction time/h Enzyme quantity/mg  L−1
PseB 37.4 0.1 37 4 14
PseC 42.3 0.1 16 4 9
PseH 18.7 0.1 16 20 17
PseG 31.3 0.5 37 4 11
PseI 38.6 0.5 37 20 18
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Optimising the PseB/PseC coupled transformation of UDP‑GlcNAc. With the Pse5Ac7Ac biosyn-
thetic enzymes in hand, we initially set out to explore the use of PseB and PseC in the first coupled transforma-
tion of the UDP-GlcNAc 4 starting material to afford PseC product UDP-4-amino-4,6-dideoxy-β-l-AltNAc 
6 (Scheme  1). This intermediate had previously proved valuable as an access point to obtaining unnaturally 
acylated Pse5Ac7Ac precursors by chemical  methods24, and also enables characterisation of the third enzyme 
in the pathway  PseH25, a potential target for inhibitor studies. However, a reaction using the C. jejuni enzymes 
and respective co-factors with 50 mg UDP-GlcNAc 4 (in negative ion ESI-LCMS analysis [M−H]− = 606.3 m/z, 
blue, consistent with the mass of UDP-GlcNAc, 607.35), only yielded a 42% conversion to the desired UDP-
4-amino-4,6-dideoxy-β-l-AltNAc 6 ([M−H]− = 589  m/z, green) by negative ion ESI-LCMS analysis (Fig.  3). 
Significant apparent starting material peak at 606 m/z also remained after 45 min, in addition to some seem-
Figure 2.  4–20% SDS-PAGE of  Ni2+-His6 purified C. jejuni Pse5Ac7Ac biosynthetic enzymes PseBCHGI.
Figure 3.  C. jejuni PseB and PseC reaction progression (a) after 45 min of incubation with UDP-GlcNAc 4, and 
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ingly unreacted PseB product UDP-4-keto-6-deoxy-β-l-IdoNAc 7 ([M−H]− = 588 m/z, red), with no increase in 
conversion noted over 6 h. This result therefore implied turnover by the PseB enzyme may be the limiting step 
in the coupled transformation, however we found increasing the PseB enzyme concentration had no effect on 
conversion. Consideration of the PseB mechanism in more detail, and noting previous biochemical characteri-
sation, revealed that in addition to acting as a 5-inverting 4,6-dehydratase, PseB can also catalyse a further C5 
epimerisation (highlighted with an asterisk in Scheme 2) of the initial product 7 to afford UDP-4-keto-6-deoxy 
GlcNAc 820,26, albeit at a lower rate. The GlcNAc configured 8 is the first intermediate en route to the biosynthesis 
of the bacterial sugar UDP-diNAcBac, integral to N-linked protein glycosylation in C. jejuni and no longer a sub-
strate for PseC in the Pse5Ac7Ac  pathway25,27. We hypothesised that our transformation might have stalled due 
to C5-epimerisation, and that the epimeric ketone products of PseB 7 and 8 (with identical ESI-LCMS peaks at 
[M−H]− = 588 m/z, red) would exist in equilibrium with their hydrated counterparts 9 and 1026. This would com-
plicate ESI analysis as the hydrates would have the same [M−H]− peak (606 m/z) as the UDP-GlcNAc 4 starting 
material, therefore the apparent remaining starting material in the PseB/C coupled reaction could instead repre-
sent epimeric hydrated PseB products 9 and 10. This suggested an excess of PseC enzyme rather than PseB may 
be required to drive the reaction forward prior to epimerisation occurring. To explore this hypothesis however it 
was necessary to clarify the ESI-LCMS analysis of the reaction and distinguish between the intermediates in the 
reaction, particularly hydrates 9 and 10 and the UDP-GlcNAc starting material 4. We therefore opted to perform 
the reaction in deuterated buffer, as during the PseB catalysed transformation incorporation of a non-exchange-
able C5-proton from bulk solvent  occurs26, as well as incorporation of a further non-exchangeable C4-proton 
from bulk solvent in the PseC catalysed transformation (Supplementary Scheme SI.1 and SI.2)28. Thus in deuter-
ated buffer we expected the [M−H]− peak in ESI-LCMS spectra (Fig. 4) of the UDP-GlcNAc starting material 4 
to be unaffected ([M−H]− = 606 m/z, blue), but the peaks to increase by 1 m/z for the PseB ketone products 11 
and 12 ([M−H]− = 589 m/z, red) and their respective hydrates 13 and 14 ([M−H]− = 607 m/z, yellow), and the 
peak to increase by 2 m/z for the PseC product 15 ([M−H]− = 591 m/z, green). Although all other exchangeable 
protons of the hydroxyl groups would also become deuterated following incubation in  D2O potentially com-
plicating analysis we anticipated that an excess of  H2O in the mobile phase during ESI-LCMS would result in 
re-exchange of these hydroxyl groups, thus enabling LCMS to be used to compare the relative conversions to the 
PseC product at different time points and ratios of PseB and PseC. Indeed when UDP-GlcNAc 4 was incubated 
with either a 1:1 or 1:5 ratio of PseB and PseC in deuterated sodium phosphate buffer for 10 min (Fig. 4a,b), the 
presence of both UDP-GlcNAc starting material 4 ([M−H]− = 606 m/z, blue), and C5-deuterated PseB hydrated 
product 13 and 14 ([M−H]− = 607 m/z, yellow) was apparent, with an increase in the relative PseC concentration 
seemingly having little affect on the progress of the PseB catalysed reaction. However after 2 h using a 1:1 ratio of 
PseB:PseC (Fig. 4c) significant C5-deuterated PseB products remained (48% of the total biosynthetic intermedi-
ates observed in ESI-LCMS) with 38% conversion to C5,C4-dideuterated PseC product 15 ([M−H]− = 591 m/z, 
green) observed, whilst increasing the relative concentration of PseB:PseC to 1:5 over 2 h (Fig. 4d) resulted in 
an increased 66% conversion to C5,C4-dideuterated PseC product, with only 20% C5-deuterated PseB products 
remaining, and no change after 24 h. Thus implying when using equimolar concentrations of PseB and PseC 
enzymes in vitro, non-productive PseB catalysed C5 epimerisation can compete with productive PseC turnover 
reducing overall enzymatic conversion. However, increasing the concentration of PseC with respect to PseB 
drives the coupled transformation forward, minimising the formation of C5 epimeric byproduct. Notably in a 
one-pot multienzyme synthesis of Pse5Ac7Ac 1, subsequent turnover of the PseC product by the next enzyme 
in the biosynthetic pathway (PseH) would likely further increase flux through the productive PseC  pathway19, 
Scheme 2.  Full C. jejuni PseB and PseC catalysed reactions in water or deuterated buffer.
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however the optimised ratio of PseB: PseC determined here would be particularly useful in the absence of PseH 
i.e. when isolated PseC product UDP-4-amino-4,6-dideoxy-β-l-AltNAc 6 is the desired target, and or when a 
non-enzymatic acylation procedure is utilised to install natural or unnatural N-acyl  groups24.  
Figure 4.  Negative ESI LC–MS monitoring relative conversion to the PseB and PseC products in deuterated 
buffer with UDP-GlcNAc 4 (a) after 10 min with equal concentrations of PseB and PseC, (b) after 10 min with a 
PseB:PseC concentration of 1:5, (c) after 2 h with equal concentrations of PseB and PseC or (d) after 2 h with a 
PseB:PseC concentration of 1:5.
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Optimising PseH turnover in vitro through co‑factor regeneration. The third step in the Pse5Ac7Ac 
biosynthesis is the transfer of an acetyl group to N4 of the PseC product 6 affording UDP-4-acetamido-4,6-
dideoxy-β-l-AltNAc 17 (Scheme 1). Enzymatically this transformation is catalysed by  PseH29,30, an aminogly-
coside N-acetyl transferase from the GNAT superfamily, and as such utilises Ac-CoA 5 as a co-factor31. Despite 
being used ubiquitously as an acetyl transfer group in vivo, the complex structure of Ac-CoA 5 makes it a high 
cost reagent, limiting its use for in vitro preparative enzymatic synthesis of Pse5Ac7Ac 1. Therefore to make the 
synthesis more economically viable, we considered strategies to reduce the amount of Ac-CoA 5 required in the 
acylation of PseC product 6. Notably chemical acetylation has been used previously to complete this transforma-
tion, and offers an enticing opportunity to install unnatural functionality into the Pse5Ac7Ac 1  backbone18,24,25. 
However the components of such chemical acetylation reactions are invariably incompatible with subsequent 
enzymatic transformations, necessitating extra purifications of biosynthetic intermediates. Therefore, instead we 
sought to explore a method for recycling Ac-CoA 5 which would be compatible with a one-pot multienzymatic 
synthesis of Pse5Ac7Ac 1 and its derivatives.
Previously the thioester acetyl thiocholine iodide 16 had been reported as a low cost acetyl transfer agent 
in the regeneration of sub-stoichiometric amounts of Ac-CoA 5 for the synthesis of citric  acid32. We therefore 
opted to apply this system for recycling Ac-CoA 5 in the PseH catalysed acetylation of 6, wherein any catalytic 
CoA thiol 18 liberated after acetylation would undergo in situ thioester exchange with the water soluble acetyl 
thioester 16, regenerating the co-factor 5 (Scheme 3). In order to ascertain the efficiency of this method a number 
of small scale three-enzyme one-pot reactions were set up with UDP-GlcNAc 4 (1 mM), PseB (25 μM), PseC 
(125 μM), PseH (50 μM), and either sub-stoichiometric Ac-CoA 5 (0.15 mM) and increasing concentrations of 
acetyl thiocholine iodide 16 (0–20 mM) or Ac-CoA 5 (0 mM) and acetyl thiocholine iodide 16 (20 mM) as a 
control. The reactions were once more monitored by negative ESI-LCMS and the relative conversion to acetylated 
PseH product 17 ([M−H]− = 631 m/z, purple) calculated as a percentage of the total biosynthetic intermediates 
remaining. In the absence of any Ac-CoA 5 and 20 mM acetyl thiocholine iodide 16 (Fig. 5a), no PseH product 
17 is observed, indicating that 16 cannot itself act as a co-factor for the reaction. Addition of sub stoichiometric 
Ac-CoA 5 (0.15 mM) alone does yield PseH product 17 (Fig. 5b) but as expected at a lower overall conversion. 
However this conversion could be increased to 66% upon addition of 2 mM acetyl thiocholine iodide 16 (Fig. 5c), 
and 72% when 16 was included at 20 mM (Fig. 5d), indicating regeneration of the catalytic Ac-CoA 5 does occur 
through in situ thioester exchange. Indeed even using lower cost sub-stoichiometric CoA thiol 18 at 0.15 mM, 
as opposed to Ac-CoA 5 could also yield 65% conversion to the PseH product 17 in the presence of 20 mM 16, 
and a conversion of 44% could still be achieved at 0.0015 mM CoA thiol 18 (Supplementary Fig. SI.8a). Similarly 
increasing the concentration of acetyl thiocholine iodide 16 from 20 to 100 mM, in the presence of 0.0015 mM 
CoA thiol 18 resulted in an increased 61% conversion to the PseH product 17 (Supplementary Fig. SI.8b). 
These conditions represent a 1000 fold decrease in the level of Ac-CoA 5/CoA 18 previously required for PseH 
 turnover19.
Optimised ‘one‑pot’ multienzyme preparative synthesis of CMP‑Pse5Ac7Ac 3. The vast reduc-
tion in co-factor requirement and cost for PseH turnover, allied to the optimisation of the PseB/C coupled 
transformation now made a ‘one-pot’ two-step multienzyme synthesis more economically viable and practical 
for production of activated CMP-Pse5Ac7Ac 3. To demonstrate, we completed the preparative scale synthesis 
and purification of CMP-Pse5Ac7Ac 3 using the optimised conditions starting from 90  mg UDP-GlcNAc 4 
(Scheme 4). We utilised the purified C. jejuni enzymes PseB, PseC (in excess), PseH (using Ac-CoA 5 regen-
eration), PseG which hydrolyses the UDP group, and the Pse5Ac7Ac synthase PseI which condenses phospho-
enolpyruvate (PEP) with the newly formed reducing terminus in the PseG product 19, to afford Pse5Ac7Ac 1 
in one-pot over 12 h. Subsequently, the newly characterised soluble CMP-Pse5Ac7Ac synthetase PseF from A. 
caviae, was added to the mixture catalysing conversion to the activated Leloir glycosyl donor CMP-Pse5Ac7Ac 3.
Scheme 3.  In situ regeneration of the acetyltransfer co-factor 5, with acetylthiocholine iodide 16, during the 
one-pot three enzyme synthesis of the Pse5Ac7Ac biosynthetic intermediate 17.
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Figure 5.  Negative ESI LC–MS analysis of relative conversion to the PseH product 17 from UDP-GlcNAc 4, 
investigating the use of acetylthiocholine iodide 16 as a regeneration factor with sub-stoichiometric amounts 
of Ac-CoA 5 (a) 0 mM Ac-CoA 5 and 20 mM acetylthiocholine iodide 16, (b) 0.15 mM Ac-CoA 5 and 0 mM 
acetylthiocholine iodide 16, (c) 0.15 mM Ac-CoA 5 and 2 mM acetylthiocholine iodide 16, and (d) 0.15 mM 
Ac-CoA 5 and 20 mM acetylthiocholine iodide 16.
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Discussion
In order to optimise the in vitro reconstitution of the biosynthesis of the bacterial nonulosonic acid sugar 
Pse5Ac7Ac 1 we have explored the relationship between the transformations catalysed by the first two enzymes in 
the biosynthetic pathway from C. jejuni, PseB and PseC. Notably PseB catalyses an undesired secondary epimeri-
sation, which poses a challenge for in vitro enzymatic synthesis of Pse5Ac7Ac 1 as the resulting epimeric product 
is no longer a substrate for  PseC20,26, but rather the PglE enzyme in UDP-diNAcBac biosynthesis, a precursor 
to N-linked glycoproteins in C. jejuni25,27. Although the enzymatic epimerisation reaction has been previously 
disclosed, the optimisation of the coupled PseB/C reaction to maximise flux through the Pse5Ac7Ac pathway 
was unexplored. We have unequivocally demonstrated that deuterium wash-in experiments enable optimisa-
tion of comparative PseB and PseC enzyme concentrations for this transformation and thus maximise desired 
conversion in ESI-LCMS experiments. It would be beneficial in further investigations to focus on determining 
the residues involved in the PseB catalysed epimerisation to reduce the need for excess PseC enzyme. Indeed 
previous mutagenesis studies have highlighted PseB active site residues which are essential for the initial inver-
sion and dehydration but seemingly play no role in the secondary  epimerisation26, thus implying that rational 
mutagenesis studies may be used to eliminate undesired byproduct formation with miminal effect on the rate 
of the desired transformation.
Furthermore in the third step in Pse5Ac7Ac biosynthesis, PseH catalysed acetylation of the 4-amino group, we 
established a method for in situ regeneration of the expensive co-factor Ac-CoA 5 using acetyl thiocholine iodide 
16 as an acetyl transfer reagent. This advance significantly increases the economic viability of in vitro enzymatic 
synthesis of Pse5Ac7Ac derivatives, and eliminates the need for multiple purification steps as is required when 
chemical acetylation is employed.
We showcased the benefits of these optimisation studies by combining PseB, PseC and PseH with the final 
two steps in the Pse5Ac7Ac pathway PseG and PseI, in the process establishing standard conditions for large 
scale production and storage of the enzymes. The CMP-Pse5Ac7Ac synthetase PseF from H. pylori 26695 has 
 previously19 been purified so we were curious as to why the majority of the expressed protein remained insoluble 
in our hands. Consideration of the constructs physiochemical parameters identified that, although not classified 
as hydrophobic (GRAVY score = − 0.34)33, the resulting protein sequence was classified as unstable in vitro with 
an instability index of 45.3. Therefore our attention turned to other CMP-Pse5Ac7Ac synthetases such as the 
enzyme encoded by Cj1311 from C. jejuni 81-17634 and a putative enzyme in A. caviae which both share similar 
sequence identity with HpPseF, 37.2% and 35.9% respectively (aligned in Clustal Omega). All three proteins 
lack transmembrane  regions35 and are predicted to be  cytoplasmic36, which is concordant with their negative 
GRAVY scores (CjPseF − 0.32 and AcPseF − 0.22). However considering their function as carbohydrate-active 
enzymes they may be membrane associated with Pse5Ac7Ac 1 activation occurring in the cytoplasm near the 
inner membrane prior to utilisation by Pse5Ac7Ac glycosyltransferases. The instability index of CjPseF was cal-
culated as 53.6 and hence predicted to be even less stable than the H. pylori counterpart. Therefore we focussed 
on AcPseF21 as it has the lower instability index (40.4) and successfully purified soluble protein obtaining a yield 
of 13 mg  L−1. Preliminary characterisation of AcPseF using SEC-MALS confirmed it existed predominantly 
(> 99%) as a homodimer in solution, and ESI-LCMS studies confirmed its activity as a bona fide CMP-Pse5Ac7Ac 
synthetase, with further biochemical characterisation a subject of future work. Additionally CD studies of the 
protein indicated it may also be amenable to crystallisation with over 86% secondary structure, consistent with 
the computational data obtained for homologous HpPseF37. AcPseF also shows 27% sequence identity to the 
CMP-Neu5Ac synthetase from Neisseria meningitidus (NmCNS), for which a 2 Å X-ray crystal structure has been 
solved with the substrate analogue CDP present in the active site and Neu5Ac 2  docked36. Unsurprisingly align-
ment of these sequences alongside HpPseF and CjPseF, in addition to CMP-Kdo synthetase  homologues22,23,38,39 
revealed conservation of several key residues, such as those involved in binding to the cytosine moiety. However 
differences in the sequence between AcPseF and NmCNS at residues predicted to bind the NHAc substituent at 
C5, which is equatorial in Neu5Ac 2, as opposed to axial in Pse5Ac7Ac 1, and the residues which are proposed to 
bind the C6 propyl chain in Neu5Ac 2 are also apparent. These differences in sequence may in-part account for 
the altered specificity for carbohydrate substrates between these enzymes. Importantly, we further demonstrated 
that the soluble AcPseF enzyme was suitable for a “one-pot” multienzymatic synthesis with the biosynthetic 
enzymes from C. jejuni, which enabled the preparative synthesis of purified CMP-Pse5Ac7Ac 3 from UDP-
GlcNAc 4. With multimilligram quantities of the activated Leloir glycosyl donor now in hand and practically 
Scheme 4.  “One-pot” chemoenzymatic synthesis of CMP-Pse5Ac7Ac 3 from UDP-GlcNAc 4 using the 
biosynthetic enzymes under optimised in vitro conditions.
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accessible, future structural studies of PseF enzymes and perhaps more crucially biochemical characterisation 
of elusive Pse5Ac7Ac glycosyltransferases are eminently more feasible.
Methods
General methods. Negative ESI LC–MS was carried out on a high performance Dionex UltiMate 3000 LC 
system (Thermo Scientific) fitted with a Waters CORTECS T3 column (2.7 μm, 150 × 2.1 mm) and linked to a 
Bruker HCTultra ETD II system (Bruker Daltonics) MS, using a 30–70% gradient of MeCN (0.1% formic acid) 
in  H2O (0.1% formic acid) over 12 min.
1D and 2D NMR spectra were recorded on a Bruker Avance Neo 700 MHz spectrometer.
C. jejuni PseB, C, H, G, I. PseB (WP_002869093.1) pET-30a and PseC (WP_002856503.1) pFO4 recom-
binant  plasmids1 were electroporated into E. coli BL21(DE3) cells and pET-15b vectors containing PseH 
(WP_002781802.1), PseG (WP_002830499.1) or PseI (WP_002870258.1) (purchased from GenScript, restric-
tion enzymes NdeI and BamHI) chemically transformed into E. coli BL21(DE3). For expression trials, cells were 
streaked onto LB agar containing appropriate antibiotics and incubated (37 °C, overnight) before inoculation of 
LB with a single colony and incubation (180 rpm, 37 °C, overnight). 2 mL of culture was added per litre of media 
and incubated (180 rpm, 37 °C) until an  OD600 of 0.6 was reached whereby aliquots of culture were subjected 
to different induction conditions. Cell pellets were collected via centrifugation (10,000×g, 10 min, 6 °C) and 
resuspended in BugBuster containing protease inhibitor tablets and treated as per the manufacturer’s instruc-
tions. Insoluble material was removed following centrifugation (10,000×g, 10 min, 6 °C) and the supernatant 
analysed via SDS PAGE (Supplementary Fig. SI.1). Large scale protein expression was carried out as above using 
the optimised inductions conditions as discussed in the main text and cell pellets were collected via centrifu-
gation (6000×g, 40 min, 6 °C) and stored at − 80 °C until required. Cell pellets were resuspended in cold lysis 
buffer (50 mM sodium phosphate buffer, pH 7.4, 400 mM NaCl, 10 mM imidazole, Benzonase (25 U/L media), 
protease inhibitor tablet) and sonicated. The supernatant following centrifugation (20, 000×g, 20 min, 6  °C) 
was loaded onto a HisTrap HP  Ni2+ affinity column pre-equilibrated with 50 mM sodium phosphate buffer, pH 
7.4, 400 mM NaCl, 10 mM imidazole. After washing (7 C.V) with the same buffer, a linear gradient of 10 mM 
to 300 mM imidazole was applied (15 C.V) and fractions containing desired protein were desalted into 25 mM 
sodium phosphate buffer, pH 7.4, 50 mM NaCl.
H. pylori PseF. H. pylori PseF (WP_001201444.1) pET-15b recombinant plasmid was electroporated into 
E. coli BL21(DE3) and E. coli Turner (DE3) cells, streaked onto  LBAmp agar and incubated (37 °C, overnight). A 
single colony of E. coli BL21(DE3) cells was used to inoculate  2xYTAmp (60 mL) and incubated (37 °C, 180 rpm, 
overnight). The culture was further diluted with  2xYTAmp (4 L) and incubated (30 °C, 180 rpm) until an  OD600 
of 0.6 was reached whereby Isopropyl-β-d 1-thiogalactopyranoside (IPTG) was added to a final concentration of 
0.1 mM and further incubated (37 °C, 180 rpm, 2.75 h). Cell pellets were collected via centrifugation (6000×g, 
30 min, 4 °C), resuspended in cold lysis buffer supplemented with 1 mM  MgCl2 and 10 mM β-mercaptoethanol 
and sonicated. The supernatant following centrifugation (17,700×g, 35 min, 4 °C) was loaded onto a HisTrap 
HP  Ni2+ affinity column pre-equilibrated with 50 mM sodium phosphate buffer, pH 7.3, 400 mM NaCl, 10 mM 
β-mercaptoethanol, and 10 mM imidazole. After washing (10 C.V) with the same buffer, a linear gradient of 
10–250 mM imidazole was applied (30 C.V) followed by 500 mM imidazole (10 C.V’s) and fractions were ana-
lysed via SDS PAGE (Supplementary Fig. SI.2). For expression trials, a single colony from E. coli BL21(DE3) 
and E. coli Turner (DE3) cells transformed with the PseF recombinant plasmid were used to inoculate  2xYTAmp 
and incubated (37 °C, 180 rpm, overnight), before being diluted in  2xYTAmp to an  OD600 of 0.02 and incubated 
(180 rpm, 37 °C). Aliquots of culture were subjected to different induction conditions and cell pellets collected 
via centrifugation (10,000×g, 10 min, 6 °C). Cell pellets were resuspended in 50 μL lysis buffer (as above) sup-
plemented with 1 mg mL−1 lysozyme and incubated (37 °C, 45 min) then centrifuged (6000×g, 10 min, 4 °C) to 
collect soluble and insoluble material. The insoluble material was resuspended in 50 μL  dH2O and all samples 
analysed via SDS-PAGE.
A. caviae  PseF40. A.  caviae PseF (WP_139737850.1) pET-28a recombinant plasmid (purchased from Gen-
Script, restriction enzymes NdeI and EcoRI) was electroporated into E. coli BL21(DE3) cells, streaked onto  LBKan 
agar and incubated (37 °C, overnight). For expression trials, a single colony was used to inoculate  LBKan (60 mL) 
and incubated (30 °C, 180 rpm, overnight) before being diluted in  2xYTAmp to an  OD600 of 0.02 and incubated 
(180 rpm, 37 °C). Expression trials were conducted by subjecting aliquots of culture to different induction con-
ditions and cell pellets collected via centrifugation (10,000×g, 10 min, 6 °C). Cell pellets were resuspended in 
BugBuster containing protease inhibitor tablets and 1 mg mL−1 lysozyme and treated as per the manufacturer’s 
instructions. Insoluble material was separated following centrifugation (10,000×g, 10 min, 6  °C) then resus-
pended in 50 μL  dH2O and all samples analysed via SDS PAGE.
Following expression trials, a single colony of E. coli BL21(DE3) cells transformed with AcPseF was used to 
inoculate  LBKan (60 mL) and incubated (30 °C, 180 rpm, overnight). The culture was further diluted with  LBKan 
(3 L) and incubated (37 °C, 180 rpm) until an  OD600 of 0.6 was reached whereby IPTG was added to a final 
concentration of 0.1 mM and further incubated (30 °C, 180 rpm, 3 h). Cell pellets were collected via centrifu-
gation (6000×g, 30 min, 4 °C), resuspended in cold lysis buffer supplemented with 1 mM  MgCl2 and 10 mM 
β-mercaptoethanol and sonicated. The supernatant following centrifugation (17,700×g, 40 min, 4 °C) was loaded 
onto a HisTrap HP  Ni2+ affinity column pre-equilibrated with 50 mM sodium phosphate buffer, pH 7.3, 400 mM 
NaCl, 1 mM  MgCl2, 10 mM β-mercaptoethanol, and 10 mM imidazole. After washing (10 C.V) with the same 
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buffer a linear gradient of 10 mM to 500 mM imidazole was applied (40 C.V) and fractions were analysed via 
SDS PAGE (Supplementary Fig. SI.3).
A. caviae PseF  characterisation40. Aliquots of AcPseF were further purified by gel filtration in 25 mM 
Tris–HCl pH 7.3 buffer containing 50 mM NaCl and 2 mM  MgCl2. Following SDS PAGE analysis, pure protein 
was extracted from bands at the expected PseF construct molecular weight and subject to trypsin digest. The 
resultant peptides were analysed by MALDI-MS and MS/MS and spectral data was compared to the Mascot 
database to identify the protein as AcPseF (Supplementary Fig. SI.4).
Following gel filtration, aliquots of AcPseF were dialysed into 25 mM sodium phosphate buffer pH 7.4 and 
analysed by circular dichroism at 30 °C, from 180 to 260 nm at a final concentration of 0.2 mg mL−1. Under these 
conditions 86.5% of AcPseF was predicted to have a fixed secondary structure, suggesting that it is amenable 
for crystallisation studies (Supplementary Fig. SI.5). Secondary structure predictions were made from circular 
dichroism data using K2D3 (http://cbdm-01.zdv.uni-mainz .de/~andra de/k2d3/).
Aliquots of AcPseF were dialysed into 20 mM Tris pH 7.8 buffer containing 50 mM NaCl and 2 mM  MgCl2 
and concentrated to 4 mg mL−1. 100 µL samples were applied to a Superdex S200 size-exclusion column (G.E. 
Healthcare) pre-equilibrated with the same buffer, attached to a system comprising of a Wyatt HELEOS-II multi-
angle light scattering detector and a Wyatt rEX refractive index detector linked to a Shimadzu HPLC system 
(SPD-20A UV detector, LC20-AD isocratic pump system, DGU-20A3 degasser and SIL-20A autosampler). A 
2.5 mg mL−1 BSA sample was run as a standard and all data analysed using Astra V software (Supplementary 
Fig. SI.6).
Reaction mixtures containing 130 μg mL−1 AcPseF, 0.5 mM Pse5Ac7Ac (Sussex Research), 1.5 mM CTP, 
1 mM  MgCl2, 50 mM NaCl, 25 mM sodium phosphate, pH 7.4, were incubated at 25 °C, alongside control reac-
tions with reaction mixture as described without either Pse5Ac7Ac 1, CTP or AcPseF. Reactions were analysed 
by-ESI LC–MS and a peak indicating the formation of CMP-Pse5Ac7Ac 3 ([M−H]− 638.2) was only observed 
in the reaction containing all components thus suggesting AcPseF functions as a CMP-Pse5Ac7Ac synthetase. 
However a peak corresponding to Pse5Ac7Ac 1 was also observed, even after 6.5 h indicating that the reaction 
had not gone to completion and/or that hydrolysis of CMP-Pse5Ac7Ac 3 was occurring (Supplementary Fig. SI.7).
PseB and PseC activity assays. PseB 25 µM and PseC 25 µM were added to reaction mixtures to give 
final concentrations of 1 mM UDP-GlcNAc, 10 mM l-Glu and 1.5 mM PLP in 50 mM Tris–HCl pH 7.4, and 
incubated (120 rpm, 37 °C). Reaction progression was monitored by -ESI LC–MS over 6 h. PseB and PseC were 
dialysed into deuterated Tris–HCl buffer (50 mM, pH 7.4) and added to reaction mixtures to give final concen-
trations of 1 mM UDP-GlcNAc, 10 mM l-Glu and 1.5 mM PLP in deuterated 50 mM Tris-HCl buffer pH 7.4. 
PseB was added to a final concentration of 25 µM and PseC to a final concentration of 25 µM or 125 µM and the 
reactions incubated (120 rpm, 37 °C). Reaction progression was monitored by -ESI LC–MS over 2 h.
PseH activity assays. PseB 25 µM, PseC 125 µM and PseH 50 µM were added to reaction mixtures to 
give final concentration of 1 mM UDP-GlcNAc, 10 mM l-Glu and 1.5 mM PLP in 50 mM sodium phosphate 
buffer pH 7.4, with varying concentrations of Ac-CoA (0 mM or 0.15 mM) or CoA (0 mM, 0.15 mM, 0.015 mM 
or 0.0015 mM) and acetylthiocholine iodide (0 mM, 2 mM, 20 mM or 100 mM). Reactions were incubated 
(120 rpm, 37 °C) and monitored by ESI LC–MS over 3 h (Supplementary Fig. SI.8).
Chemoenzymatic synthesis and characterisation of CMP‑Pse5Ac7Ac 3. A reaction mixture 
containing 2 mM UDP-GlcNAc 4 (90 mg), 0.0015 mM coenzyme-A 18, 100 mM S-acetyl thiocholine iodide 
16, 4 mM pyridoxal 5′-phosphate, 20 mM l-glutamic acid, 3 mM phosphoenolpyruvate, 0.2 mg mL−1 PseB, 
0.4 mg mL−1 PseC, 0.2 mg mL−1 PseH, 0.2 mg mL−1 PseG and 0.2 mg mL−1 PseI in 50 mM sodium phosphate 
pH 7.4 (total volume 74 mL), was incubated (37 °C, 12 h) and was monitored via ESI LC–MS for the production 
of Pse5Ac7Ac 1. After 12 h, 0.2 mg mL−1 PseF, 4 mM CTP and 20 mM  MgCl2 were added and the reaction was 
incubated (37 °C, 4 h) and monitored by ESI LC–MS for production of CMP-Pse5Ac7Ac 3. The mixture was 
lyophilised, resuspended in 1:1  dH2O:EtOH and stored at 4 °C for 30 min to precipitate enzymes which were 
then removed via centrifugation (38,759×g, 1 h, 4 °C). The supernatant was diluted in  dH2O before lyophilisa-
tion then resuspended in  dH2O and passed through a 45 µM Millex syringe filter (Merck) before being applied 
to a 500 mL column packed with Bio-Gel P-2 resin (Bio-Rad) in HPLC-grade  H2O at a flow rate of 30 mL/h. 
4 mL fractions were collected for 24 h and analysed via ESI-LC–MS for the presence 3 before being pooled and 
lyophilised to afford 3 as a colourless foam (39 mg).
1H NMR (500 MHz,  D2O) δ 8.02 (dd, J = 7.5, 1.0 Hz, 1H, H2′), 6.14 (d, J = 7.5 Hz, 1H, H1′), 6.00 (d, J = 4.1 Hz, 
1H, H3′), 4.37 – 4.32 (m, 2H, H4′, H6′), 4.32–4.28 (m, 2H, H5, H6), 4.27–4.22 (m, 4H, H4, H5′, H7a′, H7b′), 
4.15–4.09 (m, 1H, H8), 4.05–4.01 (m, 1H, H7), 2.25–2.20 (m, 1H, H3eq), 1.99 (s, 3H, 7NHAc), 1.96 (s, 3H, 
5NHAc), 1.61 (ddd, J = 13.4, 12.0, 5.2 Hz, 1H, H3ax), 1.20 (d, J = 6.5 Hz, 3H,  9CH3). 13C NMR (126 MHz,  D2O) 
δ 174.5, 173.2, 170.4, 165.8, 157.3, 141.7, 100.0, 96.5, 89.2, 82.9, 74.1, 72.7, 69.2, 68.6, 64.9, 64.38, 53.7, 48.8, 
36.0, 22.0, 21.9, 17.2. HR-MS data was collected with –ESI MS: Expected [M−H]− m/z: 638.1789, measured 
[M−H]− m/z: 638.1727. ATR-FTIR  Vmax: 3227, 2941, 2888, 1592, 1403, 1075 cm−1.
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